1. Market Research
  2. > Business Services
  3. > Research and Development Market Trends
  4. > OncoSec Medical Inc. - Product Pipeline Review - 2014

OncoSec Medical Inc. - Product Pipeline Review - 2014

  • December 2014
  • -
  • Global Markets Direct
  • -
  • 29 pages

OncoSec Medical Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct’s, ‘OncoSec Medical Inc. - Product Pipeline Review - 2014’, provides an overview of the OncoSec Medical Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of OncoSec Medical Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of OncoSec Medical Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of OncoSec Medical Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the OncoSec Medical Inc.’s pipeline products

Reasons to buy

- Evaluate OncoSec Medical Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of OncoSec Medical Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the OncoSec Medical Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of OncoSec Medical Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of OncoSec Medical Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of OncoSec Medical Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

OncoSec Medical Inc. - Product Pipeline Review - 2014
Table of Contents
OncoSec Medical Inc. Snapshot 4
OncoSec Medical Inc. Overview 4
Key Information 4
Key Facts 4
OncoSec Medical Inc. - Research and Development Overview 5
Key Therapeutic Areas 5
OncoSec Medical Inc. - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Pipeline Products - Combination Treatment Modalities 9
OncoSec Medical Inc. - Pipeline Products Glance 10
OncoSec Medical Inc. - Clinical Stage Pipeline Products 10
Phase II Products/Combination Treatment Modalities 10
Phase I Products/Combination Treatment Modalities 11
OncoSec Medical Inc. - Early Stage Pipeline Products 12
Preclinical Products/Combination Treatment Modalities 12
OncoSec Medical Inc. - Drug Profiles 13
DNA IL-12 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
DNA IL-12 + pembrolizumab 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
DNA IL-12 + Anti-CTLA-4 Antibody 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
DNA IL-12 + Anti-PD-1 Antibody 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
OncoSec Medical Inc. - Pipeline Analysis 18
OncoSec Medical Inc. - Pipeline Products by Target 18
OncoSec Medical Inc. - Pipeline Products by Route of Administration 19
OncoSec Medical Inc. - Pipeline Products by Molecule Type 20
OncoSec Medical Inc. - Pipeline Products by Mechanism of Action 21
OncoSec Medical Inc. - Recent Pipeline Updates 22
OncoSec Medical Inc. - Locations And Subsidiaries 27
Head Office 27
Other Locations and Subsidiaries 27
Appendix 28
Methodology 28
Coverage 28
Secondary Research 28
Primary Research 28
Expert Panel Validation 28
Contact Us 29
Disclaimer 29

List of Tables

OncoSec Medical Inc., Key Information 4
OncoSec Medical Inc., Key Facts 4
OncoSec Medical Inc. - Pipeline by Indication, 2014 6
OncoSec Medical Inc. - Pipeline by Stage of Development, 2014 7
OncoSec Medical Inc. - Monotherapy Products in Pipeline, 2014 8
OncoSec Medical Inc. - Combination Treatment Modalities in Pipeline, 2014 9
OncoSec Medical Inc. - Phase II, 2014 10
OncoSec Medical Inc. - Phase I, 2014 11
OncoSec Medical Inc. - Preclinical, 2014 12
OncoSec Medical Inc. - Pipeline by Target, 2014 18
OncoSec Medical Inc. - Pipeline by Route of Administration, 2014 19
OncoSec Medical Inc. - Pipeline by Molecule Type, 2014 20
OncoSec Medical Inc. - Pipeline Products by Mechanism of Action, 2014 21
OncoSec Medical Inc. - Recent Pipeline Updates, 2014 22
OncoSec Medical Inc., Other Locations 27

List of Figures

OncoSec Medical Inc. - Pipeline by Top 10 Indication, 2014 6
OncoSec Medical Inc. - Pipeline by Stage of Development, 2014 7
OncoSec Medical Inc. - Combination Treatment Modalities in Pipeline, 2014 9
OncoSec Medical Inc. - Pipeline by Top 10 Target, 2014 18
OncoSec Medical Inc. - Pipeline by Top 10 Route of Administration, 2014 19
OncoSec Medical Inc. - Pipeline by Top 10 Molecule Type, 2014 20
OncoSec Medical Inc. - Pipeline Products by Top 10 Mechanism of Action, 2014 21

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016

Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016’, provides in depth analysis on Integrin Alpha 7 (ITGA7) ...

Pulmonary Fibrosis - Pipeline Review, H2 2016

Pulmonary Fibrosis - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • September 2016
  • by Global Markets Direct

Pulmonary Fibrosis - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Pulmonary Fibrosis - Pipeline Review, H2 2016’, provides an overview of the Pulmonary Fibrosis pipeline landscape. ...

Cognitive Impairment - Pipeline Review, H2 2016

Cognitive Impairment - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • September 2016
  • by Global Markets Direct

Cognitive Impairment - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Cognitive Impairment - Pipeline Review, H2 2016’, provides an overview of the Cognitive Impairment pipeline landscape. ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.